GGrantIndex
← Leaderboards

Natalia Teleshova

Population Council

$10,140,973
Attributed
$15,683,437
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY201125
$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,683,437 · 6

By mechanism

R01$12,470,347 · 3
P50$3,155,340 · 2
P51$57,750 · 1

Most similar at Population Council

Same institution · by research overlap

Others in their field

Top investigators on “Vagina

Research focus

VaginaIn VivoContraceptive AgentsLeadWomanIn VitroHormonal ContraceptionDoseMacaca MulattaTechnology DevelopmentBaseSide EffectSafetyPregnancyVaginal FluidInnovationFormulationPreventTranscriptome SequencingViralTechnologyPreventionAnimalsContraceptive Methods

Grant awards (22)

Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections$478,398
P50 · FY2025 · HD · contact PI
Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections$889,333
P50 · FY2024 · HD · contact PI
An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV$805,684
R01 · FY2024 · AI · contact PI
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)$743,796
R01 · FY2024 · AI
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)$908,910
R01 · FY2023 · AI
An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV$857,028
R01 · FY2023 · AI · contact PI
Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections$402,693
P50 · FY2023 · HD · contact PI
An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV$987,021
R01 · FY2022 · AI · contact PI
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)$880,230
R01 · FY2022 · AI
Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections$775,366
P50 · FY2022 · HD · contact PI
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)$1,052,922
R01 · FY2021 · AI
An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV$994,388
R01 · FY2021 · AI · contact PI
Preclinical testing of a novel non-hormonal intravaginal ring to prevent pregnancy and sexually transmitted infections$609,550
P50 · FY2021 · HD · contact PI
An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV$1,068,884
R01 · FY2020 · AI · contact PI
Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)$871,184
R01 · FY2020 · AI
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue$713,593
R01 · FY2017 · AI · contact PI
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue$730,557
R01 · FY2016 · AI · contact PI
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue$682,895
R01 · FY2015 · AI · contact PI
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue$19,998
R01 · FY2015 · AI · contact PI
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue$558,160
R01 · FY2014 · AI · contact PI
Effect of sex hormones on HIV infection of cervical and rectal mucosal tissue$595,097
R01 · FY2013 · AI · contact PI
MACAQUE EXPLANT MODEL FOR MICROBICIDE TESTING$57,750
P51 · FY2011 · RR · contact PI